WEREWOLF THERAPEUTICS, INC. Gain (Loss) on Extinguishment of Debt
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Gain (Loss) on Extinguishment of Debt of -$3.35 million for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was -$3.35M.
- WEREWOLF THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was $0.00.
- WEREWOLF THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was $0.00.
- WEREWOLF THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was $0.00.
- WEREWOLF THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2023 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.35M S-4 · filed 2026-09-22 | -$3.35M S-4 · filed 2026-09-22 | ||
| 2025-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 S-4 · filed 2026-09-22 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $0.00 S-4 · filed 2026-09-22 | $0.00 S-4 · filed 2026-09-22 | ||
| 2024-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | -$553.00K derived: sum of 3 quarters · filed 2026-09-22 | -$553.00K S-4 · filed 2026-09-22 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | -$553.00K derived: sum of 2 quarters · filed 2025-11-04 | -$553.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$553.00K 10-Q · filed 2025-08-14 | -$553.00K 10-Q · filed 2025-08-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 10-K · filed 2025-03-11 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |